-74%

est. 2Y upside i

Rank

#2294

Sector

Digital Therapeutics

Est. Liquidity

~3Y

Data Quality

Data: Medium

Big Health presents a moderate upside opportunity for a job seeker, driven by its FDA-cleared digital therapeutics and expansion into the adolescent mental health market.

Last updated: March 10, 2026

Bull (35%)+100%

Big Health capitalizes on its FDA-cleared SleepioRx and DaylightRx, expanding payer coverage and employer adoption significantly. The Limbix acquisition successfully broadens its portfolio into adolescent mental health, driving revenue to ~$67.5M by 2028 and justifying a $900M valuation at 13.3x revenue, reaching the upper end of late-stage digital health multiples.

Base (45%)+30%

Big Health maintains steady growth with its core FDA-cleared products, securing additional strategic partnerships and moderate market penetration. Revenue grows to ~$40.5M by 2028, leading to a $585M valuation at 14.4x revenue, reflecting solid execution in a competitive but growing market.

Bear (20%)-40%

Intensified competition from well-funded rivals or slower-than-expected reimbursement adoption for PDTs limits growth. Revenue stagnates at ~$29.7M by 2028, leading to a down round or a lower acquisition at $270M (9.1x revenue), significantly impacting common stock value due to investor liquidation preferences.

Est. time to liquidity~2.5 years

Preference Stack Risk

severe

Investors hold $153M in liquidation preferences ahead of common stock, meaning common stock holders would receive value only after this amount is paid to preferred shareholders in an exit at or below the current estimated $450M valuation.

Dilution Risk

moderate

As a late-stage private company, further funding rounds are possible before an exit, which could lead to additional dilution for existing equity holders.

Secondary Liquidity

limited

While private markets exist, liquidity for private company shares is typically limited and not guaranteed for employees.

Commercial - UK/NHS — 3 roles

Client Success — 1 role

Commercial — 1 role

General & Administrative — 1 role

Product — 1 role

View all 7 open roles at Big Health →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Big Health's data — designed to show you've done your homework.

  • 1

    “Given the recent acquisition of Talkspace by Universal Health Services and the continued growth of competitors like Lyra and Spring Health, how does Big Health plan to differentiate and maintain its market share, particularly with its FDA-cleared PDTs?”

  • 2

    “With $27M in revenue and a recent $24M strategic funding round, what are the key commercialization strategies for SleepioRx and DaylightRx, and how will the Limbix acquisition contribute to revenue growth over the next 2-3 years?”

  • 3

    “Considering the significant total funding of $153M and the current private market conditions, what is the company's anticipated timeline and strategy for a liquidity event, and how does the preference stack impact common stock holders?”

Community

Valuation Sentiment

Our model estimates -74% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.